(JSPR) Jasper Therapeutics - Performance -78.9% in 12m
Compare JSPR with Indices, Sectors and Commodities and Bonds. Who performs better in which timeframe?
Performance Rating
-87.59%
#157 in Group
Rel. Strength
3.98%
#7640 in Universe
Total Return 12m
-78.90%
#157 in Group
Total Return 5y
-95.34%
#134 in Group
P/E -
(?) Percentile in Group
P/E Forward -
(?) Percentile in Group
PEG -
(?) Percentile in Group
FCF Yield -
(?) Percentile in Group
12m Total Return: JSPR (-78.9%) vs XBI (-14%)
5y Drawdown (Underwater) Chart
Top Performers in Biotechnology
Overall best picks of Peer Group Selected by proven GARP Predictive Metrics, sorted by Growth Rating
| Symbol | 1m | 12m | 5y | P/E | P/E Forward | PEG | EPS Stability |
EPS CAGR |
|---|---|---|---|---|---|---|---|---|
| UTHR NASDAQ United Therapeutics |
2.95% | 13.3% | 161% | 12.1 | 11 | 1.43 | 74.6% | 16.1% |
| HLN NYSE Haleon |
12.6% | 32.2% | 49.3% | 24.4 | 20.2 | 1.79 | 69.1% | 13.6% |
| AMGN NASDAQ Amgen |
-8.67% | -12.4% | 27.7% | 25.5 | 13.5 | 0.95 | 0.60% | 41% |
| LONN SW Lonza |
15.8% | 12% | 33.5% | 67.1 | 35.1 | 1.28 | 2.20% | -12.5% |
| BIM PA Biomerieux |
4.68% | 18.2% | -1.63% | 32.5 | 25.2 | 1.52 | -38.5% | -25.1% |
| KMDA NASDAQ Kamada |
14.1% | 27.3% | -5.64% | 26.6 | 23.9 | 0.96 | 32.5% | 3.93% |
| NBIX NASDAQ Neurocrine Biosciences |
21.4% | -17.2% | 1.88% | 32.3 | 21.6 | 0.27 | 68.0% | 31.9% |
| ERF PA Eurofins Scientific SE |
22.4% | 0.59% | 8.05% | 26.6 | 13.6 | 0.56 | -66.6% | -17.1% |
Performance Comparison: JSPR vs XBI vs S&P 500
XBI (SPDR S&P Biotech ETF) is the Sector Benchmark for JSPR
| Total Return (including Dividends) | JSPR | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | 24.86% | 2.02% | 2.87% |
| 3 Months | -24.41% | -15.44% | -6.42% |
| 12 Months | -78.90% | -14.02% | 9.87% |
| 5 Years | -95.34% | -26.47% | 107.51% |
| Trend Score (consistency of price movement) | JSPR | XBI | S&P 500 |
| 1 Month | 62.6% | 57% | 89.4% |
| 3 Months | -71.1% | -82.3% | -72% |
| 12 Months | -74.5% | -53.1% | 49.3% |
| 5 Years | -77.6% | -53.9% | 84.1% |
| Relative Strength (compared with Indexes) | Rank in Peer Group | vs. XBI | vs. S&P 500 |
| 1 Month | #20 | 22.4% | 21.4% |
| 3 Month | #86 | -10.6% | -19.2% |
| 12 Month | #156 | -75.5% | -80.8% |
| 5 Years | #142 | -93.7% | -97.8% |
FAQs
Does JSPR Jasper Therapeutics outperforms the market?
No,
over the last 12 months JSPR made -78.90%, while its related Sector, the SPDR S&P Biotech (XBI) made -14.02%.
Over the last 3 months JSPR made -24.41%, while XBI made -15.44%.
Over the last 3 months JSPR made -24.41%, while XBI made -15.44%.
Performance Comparison JSPR vs Indeces and Sectors
JSPR vs. Indices JSPR is Over or Underperforming
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | -16.0% | 22.0% | -76.6% | -88.8% |
| US NASDAQ 100 | QQQ | -16.3% | 20.2% | -77.0% | -90.2% |
| US Dow Jones Industrial 30 | DIA | -16.3% | 23.3% | -75.5% | -85.3% |
| German DAX 40 | DAX | -18.1% | 5.58% | -102% | -104% |
| Shanghai Shenzhen CSI 300 | CSI 300 | -16.7% | 18.6% | -75.8% | -84.5% |
| Hongkong Hang Seng | HSI | -19.5% | 8.65% | -86.1% | -91.0% |
| India NIFTY 50 | INDA | -13.6% | 22.6% | -78.5% | -81.2% |
| Brasil Bovespa | EWZ | -18.1% | 13.3% | -85.8% | -72.4% |
JSPR vs. Sectors JSPR is Over or Underperforming
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | -16.2% | 21.2% | -82.8% | -99.2% |
| Consumer Discretionary | XLY | -16.9% | 21.4% | -74.4% | -93.0% |
| Consumer Staples | XLP | -15.7% | 22.8% | -83.5% | -86.5% |
| Energy | XLE | -17.0% | 24.8% | -70.6% | -69.1% |
| Financial | XLF | -16.7% | 19.3% | -82.5% | -100% |
| Health Care | XLV | -12.2% | 29.2% | -71.3% | -73.0% |
| Industrial | XLI | -17.6% | 17.5% | -77.6% | -88.9% |
| Materials | XLB | -16.0% | 20.2% | -72.5% | -72.9% |
| Real Estate | XLRE | -15.7% | 18.7% | -79.0% | -92.4% |
| Technology | XLK | -16.9% | 18.1% | -74.3% | -85.9% |
| Utilities | XLU | -17.1% | 19.2% | -84.3% | -94.8% |
| Aerospace & Defense | XAR | -16.5% | 15.5% | -85.9% | -104% |
| Biotech | XBI | -7.94% | 22.8% | -55.5% | -64.9% |
| Homebuilder | XHB | -15.6% | 21.8% | -62.9% | -69.2% |
| Retail | XRT | -16.2% | 21.3% | -70.3% | -74.6% |